| Marquardt, Jens |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
IMMUWIN, NCT04522544: Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC |
|
|
| Recruiting | 2 | 55 | Europe | Tremelimumab, Durvalumab, Y-90 SIRT, DEB-TACE | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca, Hannover Medical School | Hepatocellular Carcinoma Non-resectable, HCC | 03/25 | 09/25 | | |
NCT04511455: Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment |
|
|
| Completed | 2 | 22 | Europe | Cabozantinib | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Ipsen | Hepatocellular Carcinoma Non-resectable, Metastatic Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 70 | Europe | DKN-01 300 mg, DKN-01 600 mg, Sorafenib | Johannes Gutenberg University Mainz, Leap Therapeutics, Inc. | Hepatocellular Carcinoma | 08/21 | 08/22 | | |
NCT06515821: Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods |
|
|
| Recruiting | N/A | 4100 | Europe, RoW | ONCOSCREEN | Firalis SA, University Medical Center Mainz | Colorectal Cancer | 12/26 | 12/26 | | |
NCT05466669: Prediction of Post-TIPS Hepatic Encephalopathy in Patients With Liver Cirrhosis |
|
|
| Recruiting | N/A | 83 | Europe | | Johannes Gutenberg University Mainz | Hepatic Encephalopathy, Liver Cirrhosis | 02/25 | 02/25 | | |
